What are the signs of resistance to the targeted drug cabozantinib?

Resistance refers to the phenomenon that after patients use drugs for a long time, the therapeutic effect of drugs on tumors gradually weakens or disappears. For the targeted drug cabozantinib (Cabozantinib), if the patient shows the following signs, it may indicate that resistance has developed:

1.Disease progression: The most intuitive sign of drug resistance is tumor progression, that is, tumor size increases or metastasis spreads. If a patient's tumor grows faster or new metastases appear after treatment with cabozantinib, it may be a sign that the drug has failed.

2.Exacerbation of symptoms: Drug resistance may lead to exacerbation of tumor-related symptoms, such as increased pain, loss of appetite, weight loss, increased fatigue, etc. The worsening of these symptoms may be due to the tumor's reduced response to drug treatment.

3.Tumor marker changes: In some cases, doctors will monitor changes in tumor markers to evaluate the effectiveness of treatment. If levels of tumor markers begin to rise during treatment, it may be a sign that the tumor's response to the drug has diminished.

4.Changes in side effects: Drug resistance may lead to the reduction or disappearance of originally effective drug side effects, or the emergence of new side effects. For example, the reduction of original side effects such as hand-foot syndrome and high blood pressure may indicate that the drug has failed.

5.Changes in drug concentration: In some cases, resistance may be related to drug metabolism or excretion. If the plasma concentration of the drug decreases, the therapeutic effect of the drug on tumors may be affected.

6.Gene mutation: In some cases, tumor cells may escape the effects of drugs through genetic mutations, leading to drug resistance. Therefore, doctors may order genetic testing to assess the development of drug resistance.

In general, for the targeted drug cabozantinib, signs of resistance may appear as disease progression, worsening of symptoms, changes in tumor markers, changes in side effects, changes in drug concentration, and genetic mutations. If patients experience these signs, they should inform their doctor promptly and conduct further evaluation and adjust the treatment plan to seek more effective treatment strategies.